我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

抗血小板治疗预防冠脉支架术后再狭窄的Meta分析

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第4期
页码:
598-602
栏目:
临床研究
出版日期:
2010-06-10

文章信息/Info

Title:
Meta-analysis on effect of anti-platelet medication on coronary stent restenosis
作者:
马正金1; 徐梅2; 张言镇3; 王敏敏1; 迟晓明1
1.潍坊医学院临床学院，山东 潍坊 261041；2.青岛市急救中心， 山东 青岛 266101；3.潍坊市人民医院急救中心，山东 潍坊 261041
Author(s):
MA Zheng-jin1;  XU Mei2;  ZHANG Yan-zhen3;  WAN Min-min1;  CHI Xiao-ming1
1.Weifang Medical College, Weifang 261042, Shandong, China; 2.Qingdao Emergency Center, Qingdao 266101, Shandong, China; 3.Department of Emergency Medicine, Weifang people’s Hospital, Weifang 261042, Shandong, China
关键词:
抗血小板; 经皮冠脉介入治疗; Meta分析
Keywords:
antiplatelet therapy;  percutaneous coronary intervention;  meta-analysis
分类号:
R973
DOI:
-
文献标识码:
A
摘要:
目的: 就冠状动脉(冠脉)支架术后有关西洛他唑、氯吡格雷、阿司匹林三联抗血小板治疗对血小板活化和聚集功能及支架内再狭窄的影响相关文献进行系统评价。方法： 计算机检索国内外公开发表的有关西洛他唑，氯吡格雷，阿司匹林对血小板聚集率、冠脉支架术后再狭窄率影响的临床随机对照试验文献，按一定标准筛选文献后进行质量评价，共纳入5篇随机对照研究文献。以Cochrane协作网的软件RevMan v5.0进行处理，主要以血小板聚集抑制率，最小管腔直径(MLD)，晚期管腔丢失，再狭窄率为评价指标，进行Meta分析。结果： 在以二磷酸腺苷(ADP)为诱导剂的血小板聚集抑制率方面，实验组与对照组之间差异无显著意义，在最小血管直径，晚期血管丢失，再狭窄率方面，试验组与对照组之间的差异存在显著意义。结论： 三联(西洛他唑+氯吡格雷+阿司匹林)抗血小板药物治疗与常规两联(氯吡格雷+阿司匹林)治疗组相比能更有效地抑制冠脉支架术后的再狭窄，但其疗效和安全性还需要大规模临床试验的证实。 抗血小板；经皮冠脉介入治疗；Meta分析
Abstract:
AIM: To provide clinical drug reference by systematically evaluating relevant literature of cilostazol, clopidogrel and aspirin triple anti-platelet medication in patients who underwent coronary stenting. METHODS: Five randomized controlled trials concerning the effect of cilostazol, clopidogrel and aspirin on platelet aggregation and coronary stent restenosis rate were retrieved and RevMan v.5.0 was used for the meta-analysis of platelet aggregation inhibition rate, minimal luminal diameter (MLD), late lumen loss, and restenosis rate for the evaluation of indicators. RESULTS: Except for the inhibition rate of ADP-induced platelet aggregation, significant differences were found between the experimental and control groups in MLD, late lumen loss, and restenosis rate for the evaluation of indicators. CONCLUSION: Compared with dual anti-platelet regime with aspirin plus clopidogrel, triple anti-platelet therapy with aspirin and clopidogrel combined with cilostazol is more efficient in suppressing restenosis after coronary stent implantation. Large-scale clinical trials are needed to confirm the efficacy and safety of the triple anti-platelet regimen.

参考文献/References

［1］Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention［J］. Circ J, 2007, 71(12):1867-1872.

［2］Ahn Y, Jeong MH, Jeong JW, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial［J］. Circ J, 2008, 72(1):35-39.

［3］ Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol［J］. Circulation, 2005, 112(18):2826-2832.

［4］Chen YD, Lu YL, Jin ZN, et al. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent［J］. Chin Med J (Engl), 2006, 119(5):360-366.

[5]Min PK, Jung JH, Ko YG, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and ·volumetric intravascular ultrasound study［J］. Circ J, 2007, 71(11):1685-1690.

[6]韩雅玲,苏庆丰,李毅,等. 冠状动脉支架术后三联抗血小板治疗对血小板功能的影响［J］. 中华内科杂志, 2006, 45(8):635-638.

[7]韩雅玲. 冠心病抗血小板治疗: 热点与展望［J］. 中华医学杂志, 2005, 85(31):2171-2172.

[8]Jadad AR, Moore A, Carroll D. Assessing the quality of reports of ran- domized clinical trials: Is blinding necessary?［J］. Control Clin Trials, 1996, 17(1):1-12.

[9]林果为,沈福民. 现代临床流行病学［M］. 上海: 上海医科大学出版社, 2000:236-242.

[10]王吉耀,Gluud C. 循证医学与临床实践［M］. 北京: 北京科学出版社, 2004:118-121.

[11]钟文昭,吴一龙,谷力加. Review Manager(RevMan)——临床医生通向Meta分析的桥梁［J］. 循证医学, 2003, (3):234-246.

[12]The Active Steering Committee. Rationale and design of ACTIVE: The atrial fibrillation Clopidogrel trial with irbesartan for prevention of vascular events［J］. Am Heart J, 2006, 151(6):1187-1193.

[13]王俊. Meta分析与现代临床思维［J］. 循证医学杂志, 2002, 2(3):139 -140.

[14]韩雅玲. 抗血小板药物在冠心病介入治疗中的应用［J］. 中国实用内科杂志, 2005, 25(1):21-23.

[15]Moher D, Pham B, Jones A. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta analyses?［J］. Lancet, 1998, 352(9128):609-613.

［16］Kjaergard LL, Villumsen J, Gluud C. Quality of randomized clinical trials affects estimates of intervention efficacy［M］. Rome： Best Evid Health Care Cochrane Colloq 7th 1999 Univ S Tommaso Daquino, 1999:57.

备注/Memo

备注/Memo:
收稿日期：2009-11-13.通讯作者：徐梅，副主任医师，主要从事心脑血管病研究 Email:doctorxumei@hotmail.com 作者简介：马正金，主治医师，硕士生Email:mazhengjin197007@126.com
更新日期/Last Update: 2010-05-20